Glatopa

Multiple Sclerosis, Relapsing Remitting Multiple Sclerosis, Carcinoma in Situ + 1 more
Treatment
1 FDA approval
20 Active Studies for Glatopa

What is Glatopa

GlatiramerThe Generic name of this drug
Treatment SummaryGlatiramer acetate is a medication made of four natural amino acids: glutamic acid, alanine, tyrosine, and lysine. It is an immunomodulator used to reduce the frequency of relapses in people with relapsing-remitting multiple sclerosis. The average molecular weight of glatiramer acetate is 5,000-9,000 daltons.
Copaxoneis the brand name
Glatopa Overview & Background
Brand Name
Generic Name
First FDA Approval
How many FDA approvals?
Copaxone
Glatiramer
2002
9

Approved as Treatment by the FDA

Glatiramer, otherwise known as Copaxone, is approved by the FDA for 1 uses such as Multiple Sclerosis .
Multiple Sclerosis
Helps manage Multiple Sclerosis

Effectiveness

How Glatopa Affects PatientsGlatiramer acetate is a mix of four amino acids (L-glutamic acid, L-alanine, L-tyrosine, and L-lysine) used to treat relapsing multiple sclerosis. It works by helping to modify the immune system processes that cause MS. Patients taking glatiramer acetate have been shown to have fewer relapses than those taking a placebo or IFNb-1a. However, some patients experience side effects after taking the drug, including chest pain, injection site side effects, and hepatic injury. There is also a chance that glatiramer acetate
How Glatopa works in the bodyGlatiramer acetate works to treat multiple sclerosis by changing how the body's immune system reacts. It binds to certain molecules on cells that are involved in MS and prevents them from causing inflammation. It also encourages the body to make anti-inflammatory cells that can cross the blood-brain barrier and produce helpful cytokines. These cells help suppress MS and can even induce production of T-regulatory cells that further suppress the disease.

When to interrupt dosage

The recommended dosage of Glatopa is contingent upon the indicated condition. The quantity of dosage fluctuates in accordance with the technique of delivery (e.g. Solution - Subcutaneous or Injection, solution - Subcutaneous) featured in the table beneath.
Condition
Dosage
Administration
Multiple Sclerosis
20.0 mg, , 20.0 mg/mL, 40.0 mg/mL
, Subcutaneous, Powder, for solution, Powder, for solution - Subcutaneous, Solution, Solution - Subcutaneous, Injection, solution - Subcutaneous, Injection, solution, Injection, Injection - Subcutaneous
Carcinoma in Situ
20.0 mg, , 20.0 mg/mL, 40.0 mg/mL
, Subcutaneous, Powder, for solution, Powder, for solution - Subcutaneous, Solution, Solution - Subcutaneous, Injection, solution - Subcutaneous, Injection, solution, Injection, Injection - Subcutaneous
Relapsing Remitting Multiple Sclerosis
20.0 mg, , 20.0 mg/mL, 40.0 mg/mL
, Subcutaneous, Powder, for solution, Powder, for solution - Subcutaneous, Solution, Solution - Subcutaneous, Injection, solution - Subcutaneous, Injection, solution, Injection, Injection - Subcutaneous
Multiple Sclerosis
20.0 mg, , 20.0 mg/mL, 40.0 mg/mL
, Subcutaneous, Powder, for solution, Powder, for solution - Subcutaneous, Solution, Solution - Subcutaneous, Injection, solution - Subcutaneous, Injection, solution, Injection, Injection - Subcutaneous

Warnings

Glatopa has two demarcated contraindications, so it should not be utilized when suffering from any of the ailments specified in the following table.Glatopa Contraindications
Condition
Risk Level
Notes
Severe Hypersensitivity Reactions
Do Not Combine
Glatiramer may interact with Pulse Frequency
Severe Hypersensitivity Reactions
Do Not Combine
Glatiramer may interact with Pulse Frequency
There are 20 known major drug interactions with Glatopa.
Common Glatopa Drug Interactions
Drug Name
Risk Level
Description
9-(N-methyl-L-isoleucine)-cyclosporin A
Major
The risk or severity of adverse effects can be increased when Glatiramer is combined with 9-(N-methyl-L-isoleucine)-cyclosporin A.
Abetimus
Major
The risk or severity of adverse effects can be increased when Glatiramer is combined with Abetimus.
Acteoside
Major
The risk or severity of adverse effects can be increased when Glatiramer is combined with Acteoside.
Antilymphocyte immunoglobulin (horse)
Major
The risk or severity of adverse effects can be increased when Glatiramer is combined with Antilymphocyte immunoglobulin (horse).
Apremilast
Major
The risk or severity of adverse effects can be increased when Glatiramer is combined with Apremilast.
Glatopa Toxicity & Overdose RiskIn mice and rats given 15 times the normal dose of glatiramer acetate, there were no reports of increased cancer risk. Tests in the lab did not find any mutagenic effects. Animals given the drug did not have any reproductive or developmental issues. If someone takes too much glatiramer acetate, they may experience severe side effects such as liver damage, loss of fat, or dead skin at the injection site. Treatment for an overdose should focus on managing the symptoms and providing supportive care.

Glatopa Novel Uses: Which Conditions Have a Clinical Trial Featuring Glatopa?

193 active trials are being carried out to determine the efficacy of Glatopa in treating Multiple Sclerosis.
Condition
Clinical Trials
Trial Phases
Multiple Sclerosis
128 Actively Recruiting
Phase 3, Not Applicable, Phase 4, Phase 2, Phase 1, Early Phase 1
Carcinoma in Situ
3 Actively Recruiting
Not Applicable, Phase 4
Multiple Sclerosis
0 Actively Recruiting
Relapsing Remitting Multiple Sclerosis
14 Actively Recruiting
Not Applicable, Phase 3, Phase 2, Phase 4, Early Phase 1

Glatopa Reviews: What are patients saying about Glatopa?

2.3Patient Review
4/29/2016
Glatopa for Relapsing Form of Multiple Sclerosis
I am joining the ranks of those who have had issues after switching from Copaxone to Glatopa. I was fine for five years while on Copaxone, but soon after being switched over in January, I developed uvitis and now I'm experiencing a flare-up that isn't responding well to prednisone.
2Patient Review
10/1/2015
Glatopa for Relapsing Form of Multiple Sclerosis
About three months ago, my insurance company switched me to the generic form of this medication. Recently, I've been feeling even more tired and have started forgetting things like appointments and conversations. I'm going to see a doctor soon to discuss this further.
1.3Patient Review
2/23/2019
Glatopa for Relapsing Form of Multiple Sclerosis
I was on copaxone for about 7 years. No increases in legions during that time. My insurance forced me to switch to generic. After 1 year on generic, legions more than doubled on brain and quadrupled on spine. Doctor immediately switched me to Gilenya. 1 year later, no advancement in legions or worsening of pain and fatigue. Thought it was just my time to get worse until looking into it again and seeing like issues; however, upon further research I discovered that this is a common occurrence with this medication changeover.
1.3Patient Review
4/20/2019
Glatopa for Relapsing Form of Multiple Sclerosis
Cigna forced me to switch from Copaxone to Glatopa, and soon after I started having severe symptoms. Numbness, tingling in my extremities, difficulty using my hands, clumsiness in one foot, and difficulty thinking are just some of the problems I experienced. This drug was a big mistake.
1Patient Review
12/12/2015
Glatopa for Relapsing Form of Multiple Sclerosis
I was moved to this generic Glatopa after 12 years on Copaxone. I had a few attacks, some minor numbness and fatigue before, but since switching to Glatopa I've had two major attacks within 3 months. The first one caused me to lose my hearing in my left ear, and now I'm having trouble with my legs - they're weak and unsteady. I'm not happy with Glatopa at all.
1Patient Review
12/30/2015
Glatopa for Relapsing Form of Multiple Sclerosis
Glatopa was a terrible switch for me after being on Copaxone for four years without any issues. I started losing feeling in my left arm and face, and the injections became more difficult and painful.
1Patient Review
2/8/2017
Glatopa for Relapsing Form of Multiple Sclerosis
I started taking Glatopa 9-15. I am a 63 year old male on disability since 10-12. I live in Florida and the summers are really bad on me. I experience extreme fatigue doing any type of activity that anyone else could do with ease. Winter is much kinder to me but I still go through a lesser severe fatigue. I do not believe that Glatopa helps.
1Patient Review
10/27/2018
Glatopa for Relapsing Form of Multiple Sclerosis
I had a lot of negative side effects with this medication, including problems with my memory and depression. I also experienced pain in my joints and fatigue. Copaxone was much better for me and didn't have any of these problems, so I had to switch back.
1Patient Review
8/16/2017
Glatopa for Relapsing Form of Multiple Sclerosis
I much preferred the copaxone to this treatment. I felt like I had more support and people actually reaching out to see if I was doing alright.

Patient Q&A Section about glatopa

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

What does Glatopa treat?

"The FDA has approved Glatopa for the treatment of MS in adults."

Answered by AI

What type of drug is Glatopa?

"The usage of Glatopa is to treat patients with relapsing forms of multiple sclerosis, including those who have experienced a first clinical episode and have magnetic resonance imaging features consistent with MS. Glatopa is the generic version of Copaxone."

Answered by AI

Is Glatopa the same as Copaxone?

"The primary difference between Glatopa and Copaxone is that Glatopa is a generic version of the latter. In other words, the active ingredient, clinical benefits, and method of administration are all identical between the two medication options; however, Glatopa is typically more affordable than Copaxone."

Answered by AI

How long does it take for Glatopa to work?

"The effects of Copaxone may not be noticeable for several months after starting injections, with most people reporting it takes six to nine months to notice an effect. In some people it may take longer for the effects to be noticeable."

Answered by AI

Clinical Trials for Glatopa

Image of Jacobs School of Medicine and Biomedical Sciences, Neurology, University at Buffalo in Buffalo, United States.

Mindset Training for MS

18 - 65
All Sexes
Buffalo, NY
People with Multiple Sclerosis (MS) often experience cognitive difficulties such as memory problems, concentration issues, and reduced processing speed. These symptoms can have a negative impact on daily functioning and overall quality of life. Previous research on cognitive rehabilitation has shown that regular training focused on memory and concentration can have positive effects on cognitive functioning, including processing speed, memory, and executive functions that support daily activities. Moreover, fMRI studies (brain scans that measure brain activity) have revealed changes in brain activation following cognitive rehabilitation. Recently, the idea has emerged that a more personalized approach could improve treatment outcomes. Specifically, researchers have identified a link between personality traits and cognitive functioning. Since every individual is different, current cognitive rehabilitation programs often fail to take these personal differences into account. In this project, the investigators aim to enhance the effectiveness of cognitive rehabilitation by focusing more closely on individual characteristics through an app-based training program. Participants will complete a 12-week app training prior to a 6-week cognitive rehabilitation program. The first app focuses on mindset training, supported by a coach. Afterwards, all participants will use a second app designed to train processing speed and memory. In addition to cognitive functioning, the investigators will also examine psychological, (neuro)biological, and social changes using questionnaires and fMRI. This research may provide valuable insights into how cognitive functioning and quality of life in people with MS can be improved. This study is funded by the National MS Fund and is a collaboration between several institutions: the Department of Health, Medical and Neuropsychology at Leiden University (The Netherlands), the University at Buffalo (USA), and Reha Rheinfelden (Switzerland).
Recruiting
New This Month
Jacobs School of Medicine and Biomedical Sciences, Neurology, University at BuffaloPriska Zuber, PhD
Have you considered Glatopa clinical trials? We made a collection of clinical trials featuring Glatopa, we think they might fit your search criteria.Go to Trials
Image of Truway Health, Inc. www.truwayhealth.com (401 E 34th Street, S11P, New York, NY 10016) in New York, United States.

Electromagnetic Resonance Therapy for Autoimmune Diseases

Any Age
All Sexes
New York, NY
The ImmuneNet study is a Phase I/II clinical trial sponsored by Truway Health, Inc. It will test whether gentle, low-frequency electromagnetic resonance (LF-EMR) can influence how immune cells communicate and synchronize with each other. The goal is to see if this "quantum-synaptic" signaling effect can help stabilize immune activity and reduce the number of autoimmune flare-ups in people living with conditions such as lupus, rheumatoid arthritis, or multiple sclerosis. Participants will receive either an active or a sham (placebo) LF-EMR session three times per week for twelve weeks. Each session is completely non-invasive. Blood samples will be collected to study cytokines (immune-system messenger molecules), gene-expression patterns, and electrical field coherence among immune cells. A machine-learning system will analyze these data to predict inflammation patterns and guide individualized treatment settings. All participant data will be securely recorded and time-stamped to ensure transparency and privacy. The expected outcome of the study is a measurable reduction in autoimmune flare frequency and symptom severity, along with improved understanding of how electromagnetic signaling might safely regulate immune function.
Phase 1 & 2
Waitlist Available
Truway Health, Inc. www.truwayhealth.com (401 E 34th Street, S11P, New York, NY 10016)Gavin Solomon, President & CEOTruway Health, Inc.
Image of John D. Dingell VA Medical Center in Detroit, United States.

Ocrelizumab for Multiple Sclerosis

18 - 75
All Sexes
Detroit, MI
This study seeks to assess the effects of long-term ocrelizumab therapy on fatigue (extreme tiredness) as well as cognition (thinking and reasoning skills, such as memory, learning and attention), in veterans with multiple sclerosis. The evaluation will involve cognitive assessment scales (to assess memory, attention and learning abilities), clinical evaluations (to assess nerve function and ability to move), and patient-reported outcome measures (in which you will answer questions about your tiredness, sleep and how you function in daily life). These assessments will occur at baseline (visit 1), 6 month (Visit-2) and 12 months (visit 3) to track changes over time.
Waitlist Available
Has No Placebo
John D. Dingell VA Medical CenterGenentech, Inc.
Image of Toronto Rehabilitation Institute in Toronto, Canada.

Balance Training with Electrical Stimulation for Multiple Sclerosis

18 - 65
All Sexes
Toronto, Canada
This study will evaluate the effects of combining balance training with electrical stimulation techniques in individuals with Multiple Sclerosis (MS). MS commonly impairs leg strength, coordination, and balance, increasing the risk of falls and reducing independence. The interventions include:Balance training only, Balance training with Functional Electrical Stimulation (FES), and Balance training with FES and Transcutaneous Spinal Cord Stimulation (TSCS). FES delivers small electrical pulses to leg muscles, while TSCS delivers electrical signals through the skin to stimulate the spinal cord and enhance motor control. The study will enroll up to 24 participants over a 3-year period. This trial is funded by MS Canada. Participants will be randomly assigned to one of three groups: (1) balance training only, (2) balance training with FES, or (3) balance training with FES and TSCS. All participants will complete 12 supervised training sessions over 6 weeks. During each session, participants will engage in interactive balance games while standing in a safety harness.Outcome assessments will be conducted at three time points: baseline (prior to training), post-intervention (after 6 weeks), and follow-up (8 weeks after training). Assessments will include: * Clinical tests of mobility and balance (Timed Up and Go:TUG, 10-Meter Walk Test:10MWT, Berg Balance Scale:BBS) * Computerized balance testing using a force plate * Questionnaires on walking ability, fear of falling, and balance confidence * Neurophysiological measures of brain-spinal cord-muscle communication before and after training
Waitlist Available
Senior-friendly
Toronto Rehabilitation Institute
Image of Disability Participation and Quality of Life (DPQOL) Laboratory in Urbana, United States.

Fall Prevention Program for Multiple Sclerosis

18+
All Sexes
Urbana, IL
The research team is conducting a study to determine if a fall prevention program designed specifically for people who use wheelchairs and scooters can help people better prevent and manage falls compared to the standard of care. This study will compare two groups of participants: 1. One group will use the iROLL-O+ app, which offers personalized fall prevention tools and strategies. 2. The other group will receive fall prevention information from a well-known program developed by the Centers for Disease Control and Prevention (CDC), called STEADI, which stands for Stopping Elderly Accidents, Deaths, and Injuries. This study includes adults living with Spinal Cord Injury (SCI) or Multiple Sclerosis (MS) who use a wheelchair or scooter every day. The research team aims to determine which approach is more effective in reducing falls and improving confidence in performing daily activities.
Waitlist Available
Has No Placebo
Disability Participation and Quality of Life (DPQOL) Laboratory
Have you considered Glatopa clinical trials? We made a collection of clinical trials featuring Glatopa, we think they might fit your search criteria.Go to Trials
Image of Brigham & Women's Hospital in Boston, United States.

[F-18]FDG-PET for MS

18 - 70
All Sexes
Boston, MA
Given the need for better diagnostic imaging techniques in multiple sclerosis (MS), the study aims to investigate the utility of \[F-18\]FDG positron emission tomography (PET) in MS. The study will be assessing glucose consumption patterns in subjects with progressive MS and relapsing-remitting MS (RRMS), as well as healthy controls. PET will be compared to magnetic resonance imaging (MRI) lesion load and brain atrophy, and serum and blood biomarkers, as well as clinical measures of physical disability, cognitive impairment, fatigue, and depression. This study's findings may pave a path for integrating \[F-18\]FDG-PET in routine clinical practice for MS, improving patient experiences and outcomes. The specific aims of the study are: Aim 1: To compare glucose consumption in the brain in subjects with progressive MS, relapsing-remitting MS (RRMS), and healthy controls, using the radiolabeled glucose analogue 18-fluorodeoxyglucose, also known as \[F-18\]FDG. Aim 2: To compare the relationship between FDG-PET and standard 3T MRI measures including global and regional brain atrophy and lesion load, and to compare FDG-PET with MRI in terms of their relationship with clinical measures of physical disability, cognitive impairment, fatigue and depression in MS subjects. Aim 3: To assess the relationship of FDG-PET with serum and blood biomarkers, including but not limited to sNfL, GFAP, IL-6, and TNFα in MS.
Phase 4
Waitlist Available
Brigham & Women's HospitalTarun Singhal, MD, MBBSGenzyme, a Sanofi Company
Image of Mayo Clinic in Rochester, United States.

Autonomic Function Testing for Multiple Sclerosis

18 - 50
All Sexes
Rochester, MN
This study looks to characterize gradients of dysfunction in the autonomic nervous system in patients with clinically diagnosed multiple sclerosis. The autonomic nervous system plays key roles in regulation of blood pressure, skin blood flow, and bladder health- all issues that individuals with multiple sclerosis typically suffer. Focusing on blood pressure regulation, the most precise metric with broad clinical applicability, the investigators will perform laboratory-based tests to probe the body's ability to generate autonomic responses. For both individuals with multiple sclerosis and uninjured controls, laboratory-based experiments will utilize multiple parallel recordings to identify how the autonomic nervous system is able to inhibit and activate signals. The investigators anticipate that those with autonomic dysfunction with multiple sclerosis will exhibit abnormalities in these precise metrics. The investigators will look to see if any substantial connections exist between different degrees of preserved autonomic function and secondary autonomic complications from multiple sclerosis. In accomplishing this, the investigators hope to give scientists important insights to how the autonomic nervous system works after multiple sclerosis and give physicians better tools to manage these secondary autonomic complications.
Recruiting
Has No Placebo
Mayo Clinic
Have you considered Glatopa clinical trials? We made a collection of clinical trials featuring Glatopa, we think they might fit your search criteria.Go to Trials
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Terms of Service·Privacy Policy·Cookies·Security